06/09 Taiwan BIO Weekly
2025-06-09 |
| Taiwan BIO Weekly |
| OBI Pharma enters ADC collaboration with TegMine therapeutics utilizing GlycOBI and TegMiner enabling technologies Press release 6 June, 2025 OBI Pharma, Inc. (TW: 4174), a clinical-stage global oncology company specialized in the development of novel cancer therapies such as antibody-drug conjugates (ADCs), and TegMine Therapeutics, Inc. (TegMine), a US Biopharma specialized in developing best-in-class antibodies targeting cancer glycans and glycoproteins, have entered into an ADC-related Master Services Agreement (MSA). More... |
| Bora Pharmaceuticals to expand production in the US 5 June, 2025 Bora Pharmaceuticals (TW: 6472), Taiwan's largest CDMO (Contract Development and Manufacturing Organization), is expanding its manufacturing footprint in the US in a bid to become a full-fledged US-based pharmaceutical manufacturer, with its announcement that it plans to build an aseptic manufacturing line at its Maple Grove facility in Minnesota, USA. More... |
| Shine-On BioMedical's SOA101 antibody advances in US and Taiwanese clinical trials 5 June, 2025 Shine-On BioMedical (TW: 6926) announced that its SOA101 nano-sized trispecific T-cell engager antibody has passed regulatory reviews in both the US and Taiwan, allowing the company to initiate Phase I/IIa human clinical trials in both regions. The trials aim to evaluate the treatment's effectiveness against five difficult-to-treat cancers: lung cancer, colorectal cancer, breast cancer, ovarian cancer, and head and neck cancers. Currently, no trispecific antibody has been approved for market anywhere in the world. Shine-On's innovative design has been recognized as one of the top 10 trispecific antibody development technologies globally. The company also plans to conduct global, multi-national, multi-center clinical trials, aiming to facilitate global market entry post-approval and enhance the international visibility of Taiwan’s biopharmaceutical industry. More... (in Chinese) |
| Sofiva Genomics announces push into cancer screening market 4 June May, 2025 Taiwan genetic testing company Sofiva Genomics (TW: 6615) announced it will deepen its dual focus on maternal-fetal medicine and cancer precision medicine, actively entering the cancer screening market and expanding its presence in the Asia-Pacific region. The company stated that this year it will introduce blood-based ctDNA genetic testing technology, supported by clinical evidence published in the New England Journal of Medicine (NEJM). More... (in Chinese) |
| Taiwan's KMUH inks MoU with AbbVie to accelerate global clinical trials and advance patient-centered innovation 3 June, 2025 To accelerate clinical trial activation and execution, enhance research quality, and strengthen international competitiveness, Taiwan's Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH) has officially signed a Memorandum of Understanding (MoU) with AbbVie, a globally renowned biopharmaceutical company. More... |
| PharmaEssentia eyes expanded US use of Besremi after positive Phase III data 3 June, 2025 Taiwanese biotech PharmaEssentia (TW: 6446) is preparing to seek an expanded US label for its long-acting interferon Besremi (ropeginterferon alfa-2b) following new late-stage data that show the therapy outperforms anagrelide in treating essential thrombocythaemia (ET) after hydroxyurea failure. More... |
| Taiwan's BRIM Biotechnology to advance clinical trials for 4 new eye drugs 3 June, 2025 BRIM Biotechnology (TW: 6885) Chair Lin Chun said the company will advance clinical trials for four new eye drugs this year. Lin said BRIM Biotechnology's new dry eye treatment, BRM421, has completed formulation and concentration optimization. The company submitted a human clinical trial application for the drug to the US Food and Drug Administration in May, per CNA. More... |
| How this Taiwanese hospital enhances supply chain management with advanced analytics 2 June, 2025 Chang Gung Memorial Hospital, Linkou in Taoyuan City, Taiwan, has been validated for Stage 6 of the HIMSS Analytics Maturity Assessment Model. The AMAM measures an organisation's capabilities in healthcare analytics. More... |
| MegaPro Biomedical's anticancer drug MPB-1734 meets Phase I clinical trial endpoints 1 June, 2025 MegaPro Biomedical (TW: 6827) announced that its anticancer drug MPB-1734, developed using its nano-micelle technology platform, has achieved its Phase I clinical trial endpoints. MPB-1734 is a new formulation of cabazitaxel that excludes Tween-80. The company noted that Phase I data shows MPB-1734 reduces common hematologic and gastrointestinal side effects associated with cabazitaxel (marketed as Jevtana, also known as CBZ). More... (in Chinese) |
| AI-driven drug startup Yoda Pharmaceuticals debuts on Emerging Stock Board 29 May, 2025 Yoda Pharmaceuticals (TW: 7829) held its pre-listing investor conference recently where it announced that it is scheduled to debut on the Emerging Stock Board on June 3. Its flagship product YA-101, developed for the treatment of multiple system atrophy (MSA), is expected to complete Phase II clinical trials by the third quarter of 2026. In the fourth quarter of this year, Yoda plans to launch a NT$600 million fundraising round to support the Phase III trial for YA-101 starting in Q4 2026, as well as a Phase III trial for YA-102, which targets Parkinson’s disease. More... (in Chinese) |
| ========================================= |
| Taiwan Bio Industry Organization (Taiwan BIO) Contact: Daisy Tsai Tel: +886 2 27836028 ext 14 FAX : +886 2 27836027 Mobile: +886 933-139647 | Line ID : daisy222 Email: daisy@taiwanbio.org.tw BIO Asia-Taiwan 2025 (23-27 July, 2025) ========================================= Taiwan Bio Industry Organization (Taiwan BIO) Room C229, Bldg. C, No.99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ========================================= |